spacer
home > ict > winter 2008 > the power of communication
PUBLICATIONS
International Clinical Trials

The Power of Communication

In an increasingly globalised sector, Mark Woolf of Almac Clinical Services evaluates the challenges of clinical trial distribution in emerging markets

The current global nature of clinical trials and the push towards new markets continues to pose fresh challenges. Never has it been more crucial to understand how the clinical supply chain must be managed to access these new markets, be equipped to assess the pitfalls associated with less developed countries and identify what can be done to combat these weaknesses. We look at the relationships between all parties involved in the clinical supply chain and how their roles contribute to successful global IMP distribution.

The challenges presented to every distribution manager for the shipping of clinical trial materials to emerging markets are often identified early with the customer. Patient recruitment is now spreading to countries that have not previously had access to clinical trials. There are also countries that, although clinical trials have been established for three to four years, still present challenges to the IMP professional due to the existence of complex regulatory systems.

Many new trials are being located in countries that often do not have a robust infrastructure or a regulatory system that is tailored for clinical trials. Together these factors produce many of the common pitfalls often associated with emerging markets. China, India and regions such as Eastern Europe, South America and South East Asia all present their own unique challenges to distribution.

Factors leading to globalisation include countries that have now developed economically and have significant populations that can offer excellent patient recruitment opportunities. There is also a greater awareness of clinical trials. Eastern European countries, inaccessible for over 50 years, now offer significant patient recruitment potential and more opportunities to expand the reach of the clinical supply networks, despite regulatory challenges.

DIFFICULTIES FOR IMP LOGISTICS

With new countries and economies come the difficulties of distribution. Studies that are distributed to multiple countries will be subject to different conditions, both environmental and regulatory. Depending on the geographical location of a country, challenges include:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Woolf worked for 22 years in distribution and supply chain management within the British Armed Forces after leaving full-time education. In 2007 he joined Almac Clinical Services as the Distribution Depot Manager and is responsible for the management of the 20 Almac third-party contracted depots. Mark is responsible for expanding the depot network and managing relationships between the depots and Almac.
spacer
Mark Woolf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement